Introduction

58
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the cystic fibrosis However, in a recent study of CF P. aeruginosa isolates in Northern Europe, 60% were 74 multidrug resistant with 28% and 56% resistant to tobramycin and ciprofloxacin, ) in sterile saline. The MBC of LL37 was 149 determined as the lowest concentration at which there was no growth on the plate.
150
Synergy was defined as a ≥2 log10 decrease in total viable count (TVC) compared to 151 the starting inoculum and as a ≥2 log10 decrease in TVC by the combination compared 152 to the most active single agent [25] . Results are expressed as mean CFU/ml ±SD. that previously used by Reznikov et al. [22] . Ivacaftor was dissolved in DMSO and 159 time-kills were also performed using DMSO (0.32%) as a reagent control.
160
Subsequently, time-kill assays were performed with these isolates to compare the 
165
For synergy studies, ivacaftor was used at a concentration of 32 mg/L in combination 166 with tobramycin at 0.5 MIC. Tobramycin was chosen for synergy studies as it is the 167 most frequently prescribed inhaled antibiotic in CF and is also frequently prescribed 168 for treatment of acute infective exacerbations [2] . A no drug control was used in each 169 assay.
170
Bacterial cultures and antibiotics were incubated at 37°C under aerobic or 171 microaerophilic (5% CO2 for Streptococci) conditions. Killing activity was assessed at 0, 2, 4, 6 and 24 h by carrying out serial dilutions in sterile saline (10 
In vivo activity using a mouse model of intraperitoneal infection
190
The in vivo activity of ivacaftor was determined using a systemic sepsis model of 
Bactericidal activity of ivacaftor
245
When tested alone, ivacaftor demonstrated no antimicrobial activity against P.
246 aeruginosa at any concentration tested (Fig. 1A) . In contrast, at the highest 247 concentration tested, 32 mg/L, bacteriostatic activity was apparent against all S.
248
aureus isolates tested (Fig. 1B) . Similarly, bacteriostatic (n=3 isolates) and bactericidal
249
(n=2 isolates) activity was apparent against Streptococcus spp. isolates (Fig. 1C ) at 250 this concentration with no effect apparent against any genera at lower concentrations.
251
DMSO (0.32%) had no effect on bacterial growth in any assay. Individual time-kill 252 curves are presented for P. aeruginosa ( Supplementary Fig. 1 ), S. aureus 253 ( Supplementary Fig. 2 ) and Streptococcus spp. isolates ( Supplementary Fig. 3 .).
254
The change in CFU/mL in the presence of ivacaftor, ciprofloxacin or untreated control 255 at 24 hours for isolates within each genus is summarised in against 2/21 isolates tested, both of which were clinical Streptococcus spp.
259
There was no synergy between ivacaftor and tobramycin against P. aeruginosa ( 
Effect of ivacaftor on biofilm formation
266
Biofilm formation was classified as non-adherent, weak, moderate or strong; 2/5 P. spp., n=3/3) across the other genera tested (Fig. 3) . DMSO (0.32%) had no effect on 278 bacterial adherence in any assay. isolates. However, no synergistic activity was apparent against P. aeruginosa. In contrast to our findings, it has been previously reported that LL37 and tobramycin in 314 combination demonstrate enhanced killing of P. aeruginosa biofilms [28] . However, 315 the concentration of both LL37 (640 mg/L) and tobramycin (160-2560 mg/L) used in 316 this biofilm killing study were considerably higher than those used in the present study 317 which ranged from 1-64 mg/L and 0.25-3 mg/L for LL37 and tobramycin, respectively.
318
Synergy may also have been apparent in our study if we had used both LL37 and 319 tobramycin at higher concentrations. Despite the excellent antimicrobial activity 320 demonstrated by LL37 and HβD-3, we were unable to perform further work such as 321 biofilm assays due to the high cost of these AMPs.
322
As previous studies have reported that ivacaftor, a first-in-class CFTR potentiator, has 
347
In addition to clinical outcomes, the effect of ivacaftor treatment on the CF lung There are a number of limitations to this study. Firstly, the AMPs used were expensive 401 restricting the volumes that could be used for testing; therefore, we could not 
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Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from 
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NCTC 10713
28.5 >200 >200 18.6 >200 >200
Achromobacter (n=3) 36.6->200* >200 >200 50.6->200* >200 >200
S. maltophilia (n=3) 3.3-34.6 >200 47.7->200* 9.6-29.4 51.5->200* >200
*only active against 1 isolate Table 2 . Mean log change in CFU/ml (±SD) at 3 hours to determine synergistic activity between LL37 and tobramycin. C041 V1S1A  ATCC 27853  B087 V1S1A  B038 V1S1A  B008 V2E1B  B042 V2E1A  ATCC 29213  B024 V1S1D  B003 V1S1T  C063 V1S1B  NCTC 10713  B064 V2S2K  B125 V1S1A  B046 V1S1E  B041 V1S1K  B074 
B008 V1S1C
